The SCCS has just published its Opinion on the safety of the cosmetic preservative Climbazole, taking in account the combined use of several types of products that contain it. This Opinion was adopted as an addendum, and adopted during the plenary meeting of 24-25 October 2017. The Scientific Committee considered that it was about revision of the calculation only, and did not open a commenting period.
Background
The cosmetic ingredient Climbazole (CAS 38083-17-9), with the chemical name 1-(4-chlorophenoxy)-1-imidazol-1-yl-3,3-dimethyl-2-butanone, is currently regulated in the Cosmetics Regulation (EC) 1223/2009 as a preservative in Annex V, entry 32, up to a maximum authorized concentration of 0.5%.
In view of the on-going debate on the decreasing palette of authorised preservatives as well as the fact that less than 1% of products launched in the EU between 2010-2015, as per specific product categories, contained Climbazole, in April 2017, Cosmetics Europe submitted to the Commission services new margin of safety data including a proposal for reduced concentrations of Climbazole for use in different product types.
For full background information, see the articles
•
Climbazole: a new request for Opinion to SCCS
of 5 July 2017
•
SCCS: Revision of the Opinions Climbazole and DEGEE
of 10 July 2013
•
SCCS: 2 Opinions on Climbazole
, of 5 March 2013
•
Climbazole: a request for the SCCS Opinion
, of 29 September 2012
Opinion
1. In light of the new margin of safety data provided, does the SCCS consider safe the use of Climbazole (CAS 38083-17-9) as a cosmetic preservative in hair lotion and foot care with a maximum concentration of 0.31 % …
